糖尿病

订阅

MedSci主页 / 所有栏目 / 糖尿病

ADA 2014：纪立农教授报告磺脲类失效的预测标志物的研究探索

2014-06-15 MedSci MedSci原创

ADA磺脲类标志物纪立农
关注

本期ADA-CMT中国专场研究巡礼将为您呈现第5项项入选研究、北京大学人民医院纪立农教授领导的“磺脲类失效的预测标志物研究”。[报告时间：6月13日15:40~16:00，地点：S-302(South Building)]。        纪立农教授磺脲类药物是在临床上广泛应用的治疗2型糖尿病的降糖药。磺脲类药物治疗失

本期ADA-CMT中国专场研究巡礼将为您呈现第5项项入选研究、北京大学人民医院纪立农教授领导的“磺脲类失效的预测标志物研究”。[报告时间：6月13日15:40~16:00，地点：S-302(South Building)]。

        纪立农教授

磺脲类药物是在临床上广泛应用的治疗2型糖尿病的降糖药。磺脲类药物治疗失效也是常见的临床现象。为进一步提高磺脲类药物治疗的有效性，近年来研究者们开始探索如何预测磺脲类失效。纪立农教授团队在参加格列本脲治疗并随访48周的747例2型糖尿病患者中分别从遗传学和临床指标两条途径探索预测磺脲类失效的预测指标。

结果为，40个涉及磺脲类代谢相关的单核苷酸多态性(SNP)位点与磺脲类失效率之间并无相关性，而基线血糖处置指数DIb联合早期疗效指标能较好地预测磺脲类失效。

现场报告看点

在评选过程中，一部分评审专家认为，该研究或许是开发治疗糖尿病的个体化药物过程中的重要一步;有的评审专家则认为，对磺脲类治疗失效的预测物要求太高，推广应用可能有困难。在本届ADA-CMT中国专场征集到的23项研究中，该研究是评审意见分歧较大的。在ADA这个更大的舞台上展示这项研究，分歧是否也存在于国外学者之间?

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=20781, encodeId=d52f20e8136, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:44:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840808, encodeId=97f3184080821, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jun 16 07:32:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264502, encodeId=e617126450287, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Jun 17 11:32:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442137, encodeId=2f7f144213ef6, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Tue Jun 17 11:32:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077967, encodeId=742c20e796776, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Nov 03 02:32:00 CST 2014, time=2014-11-03, status=1, ipAttribution=)]
    2015-04-11 x35042875

    国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=20781, encodeId=d52f20e8136, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:44:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840808, encodeId=97f3184080821, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jun 16 07:32:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264502, encodeId=e617126450287, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Jun 17 11:32:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442137, encodeId=2f7f144213ef6, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Tue Jun 17 11:32:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077967, encodeId=742c20e796776, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Nov 03 02:32:00 CST 2014, time=2014-11-03, status=1, ipAttribution=)]
    2014-06-16 hukaixun

    #标志物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=20781, encodeId=d52f20e8136, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:44:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840808, encodeId=97f3184080821, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jun 16 07:32:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264502, encodeId=e617126450287, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Jun 17 11:32:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442137, encodeId=2f7f144213ef6, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Tue Jun 17 11:32:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077967, encodeId=742c20e796776, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Nov 03 02:32:00 CST 2014, time=2014-11-03, status=1, ipAttribution=)]
    2014-06-17 般若傻瓜

    #ADA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=20781, encodeId=d52f20e8136, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:44:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840808, encodeId=97f3184080821, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jun 16 07:32:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264502, encodeId=e617126450287, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Jun 17 11:32:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442137, encodeId=2f7f144213ef6, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Tue Jun 17 11:32:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077967, encodeId=742c20e796776, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Nov 03 02:32:00 CST 2014, time=2014-11-03, status=1, ipAttribution=)]
    2014-06-17 passed water

    #磺脲类#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=20781, encodeId=d52f20e8136, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:44:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840808, encodeId=97f3184080821, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jun 16 07:32:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264502, encodeId=e617126450287, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Jun 17 11:32:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442137, encodeId=2f7f144213ef6, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Tue Jun 17 11:32:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077967, encodeId=742c20e796776, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Mon Nov 03 02:32:00 CST 2014, time=2014-11-03, status=1, ipAttribution=)]
    2014-11-03 bshuang

    #纪立农#

    0

相关资讯

ADA 2014：计划委员会主席介绍大会热点

        当地时间6月13~17日，第74届美国糖尿病学会(ADA 2014)年会将在美国旧金山举行。ADA 2014计划委员会主席达莱西奥(David A.D'Alessio)介绍，今年会议涵盖糖尿病相关的八大主题：①急、慢性并发症，②行为医学、临床营养、教育和运动，③临床糖尿病/治疗，④流行病学和遗传学，

JAMA：肥胖糖尿病患者治疗 减重手术更佳（SOS研究）

        相继《柳叶刀》(Lancet)6月7日为迎接美国糖尿病学会(ADA2014)年会的来临而退出糖尿病重点号之后，《美国医学会杂志》(JAMA)也不甘人后，6月11日的JAMA当期主题也是糖尿病。当期一项比较常规治疗与减重手术治疗肥胖的研究显示，在肥胖2型糖尿病患者中，与常规治疗相比，减重手术与体重减轻

ADA 2014：降糖：脂肪肝新疗法？

ADA大会上中国专场研究巡礼将为您呈现第4项入选研究、南京大学医学院附属鼓楼医院教授领导的“艾塞那肽、胰岛素、吡格列酮对新诊断2型糖尿病患者肝脏脂肪含量及体脂分布的影响”研究。[报告时间：6月13日15:20~15:40，地点：S-302(South Building)]。 研究背景：降糖可以减少肝脏脂肪含量?       

JAMA：胰岛素类似物并非物有所值

为迎接美国糖尿病学会(ADA2014)年会的到来，《美国医学会杂志》(JAMA)11日刊登的一项研究显示，过去十年间胰岛素类似物应用率升高导致相关费用显著升高，但无确切证据显示2型糖尿病患者从中获益。此项回顾性研究利用个人保险数据库纳入123486例18岁以上2型糖尿病患者，受试者至少连续投保2年，并且至少开具过1次胰岛素处方。结果为，胰岛素处方开具比率由2000年的9.7%升至2010年15.1

ADA 2014：关注糖尿病患者抑郁症的诊治

美国糖尿病学会第74届年会(ADA2014)于当地时间6月13~17日在旧金山举行，会议第一天会场已人头攒动。今年设置的“专家面对面”(meet-the-expert)环节在会议首日下午两个时段多个并行会场安排了18个话题的讨论。其中“抑郁与糖尿病”由两位临床心理学家主持，这是一个“没有幻灯片、没有主题讲者、听众自由提问并参与讨论”的高度互动性论坛。 当被问及如何有效筛查糖尿病患者中的抑郁症、以

ADA 2014罕见的永久性新生儿糖尿病(PNDM)——来自21例患者的中国经验

美国糖尿病学会第74届年会(ADA2014)于当地时间6月13~17日在旧金山举行，会议上报道一项来自中国的研究——21例罕见的永久性新生儿糖尿病。永久性新生儿糖尿病(PNDM)罕见，治疗经验缺乏。中国医学科学院北京协和医院肖新华教授研究组收集了21例患者资料，其中10例在6~12月龄间诊断者未检出已知基因突变。在11例6月龄之前诊断的患儿中，通过分子遗传学检测确认了8例的致病性单基因突变[GCK